SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 17, 2013
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Registrant’s telephone number, including area code: (832) 934-1825
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On January 17, 2013, David Becker informed the Company that he will resign as Chief Financial Officer of Pernix Therapeutics Holdings, Inc. (the “Company”), due to personal reasons, effective March 31, 2013. Mr. Becker will be paid his current base salary through the effective date of his resignation. Mr. Becker has agreed to continue in a consulting role with the Company following his resignation.
On January 18, 2013, Charles Hrushka stepped down as Vice President of Sales & Marketing of the Company effective immediately. Mr. Hrushka will be paid his current base salary through the effective date of his resignation. Mr. Hrushka has agreed to continue in a consulting role with the Company.
On January 24, 2013, the Company issued a press release announcing the restructuring and integration of the Company’s sales force following its acquisition of Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. on December 31, 2012. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.